Overview

• Spain’s Fundación Pasqual Maragall spotlights caregiver strain, reporting that most caregivers are women dedicating about 70 hours a week, many without formal training, and urges integrated health, social and labor policies.
• Researchers linked to the Barcelonaβeta Brain Research Center report tests that can flag Alzheimer’s risk 15–20 years before symptoms with about 98% precision, as Europe’s approval of lecanemab moves into price talks in Spain with limited patient eligibility.
• Recent trials of monoclonal antibodies such as lecanemab and donanemab show roughly 27–29% slowing of decline but carry risks including brain edema and microhemorrhages, intensifying scrutiny over clinical benefit, safety and access.
• Clinicians emphasize practical habits to delay decline or improve quality of life, highlighting the “three Cs” — crosswords, company and walking — alongside regular exercise, cognitive stimulation and social engagement.
• Public‑health and community efforts expand ahead of 21 September, with Peru logging 49,532 Alzheimer’s‑related care visits so far in 2025 and local groups in Spain organizing talks, memory activities, chess events and workshops.